Status:
COMPLETED
Alternate Day Buprenorphine Administration, Phase IX - 14
Lead Sponsor:
University of Vermont
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
22-51 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.
Eligibility Criteria
Please contact site for information.
Key Trial Info
Start Date :
March 1 1992
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000232
Start Date
March 1 1992
Last Update
May 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Treatment Research Center
Burlington, Vermont, United States, 05401